1. Home
  2. PROC vs RDIB Comparison

PROC vs RDIB Comparison

Compare PROC & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROC
  • RDIB
  • Stock Information
  • Founded
  • PROC 1976
  • RDIB 1937
  • Country
  • PROC Luxembourg
  • RDIB United States
  • Employees
  • PROC N/A
  • RDIB N/A
  • Industry
  • PROC Biotechnology: Pharmaceutical Preparations
  • RDIB Movies/Entertainment
  • Sector
  • PROC Health Care
  • RDIB Consumer Discretionary
  • Exchange
  • PROC Nasdaq
  • RDIB Nasdaq
  • Market Cap
  • PROC 203.1M
  • RDIB 162.8M
  • IPO Year
  • PROC N/A
  • RDIB N/A
  • Fundamental
  • Price
  • PROC $1.10
  • RDIB $6.49
  • Analyst Decision
  • PROC
  • RDIB
  • Analyst Count
  • PROC 0
  • RDIB 0
  • Target Price
  • PROC N/A
  • RDIB N/A
  • AVG Volume (30 Days)
  • PROC 68.7K
  • RDIB 5.5K
  • Earning Date
  • PROC 11-26-2024
  • RDIB 12-03-2024
  • Dividend Yield
  • PROC N/A
  • RDIB N/A
  • EPS Growth
  • PROC N/A
  • RDIB N/A
  • EPS
  • PROC 0.52
  • RDIB N/A
  • Revenue
  • PROC $414,096,000.00
  • RDIB $197,270,000.00
  • Revenue This Year
  • PROC $5.54
  • RDIB N/A
  • Revenue Next Year
  • PROC $8.54
  • RDIB $13.64
  • P/E Ratio
  • PROC $1.11
  • RDIB N/A
  • Revenue Growth
  • PROC N/A
  • RDIB N/A
  • 52 Week Low
  • PROC $0.50
  • RDIB $5.96
  • 52 Week High
  • PROC $4.95
  • RDIB $21.34
  • Technical
  • Relative Strength Index (RSI)
  • PROC 41.91
  • RDIB 42.22
  • Support Level
  • PROC $0.50
  • RDIB $5.96
  • Resistance Level
  • PROC $1.76
  • RDIB $6.78
  • Average True Range (ATR)
  • PROC 0.18
  • RDIB 0.44
  • MACD
  • PROC -0.06
  • RDIB -0.01
  • Stochastic Oscillator
  • PROC 44.44
  • RDIB 24.44

About PROC Procaps Group S.A.

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.

Share on Social Networks: